This study will investigate whether within BR grade 3 ER/PR+ or HER2+ breast cancers the percentage of homologous recombination deficiency is substantially higher in metastatic lesions compared to primary breast cancers.
ID
Bron
Verkorte titel
Aandoening
Breast cancer
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The percentage of biopsies from local recurrent or metastatic lesions showing HRD among patients with BR grade 3 ER/PR+ or HER2+ breast cancer.
Achtergrond van het onderzoek
The ex vivo assessment of Repair Capacity (RECAP) test in advanced breast cancer patients is an extension of the HRD pilot study. In previous studies we have investigated percentages of homologous recombination deficient (HRD) tumors on primary tumor samples as well as on biopsies of metastatic lesions within all subtypes of breast cancer. We observed that within the TNBC the percentage of HRD tumors was more or less similar in primary and metastatic breast cancer. Whereas, we found that within the BR grade 3 ER/PR+ or HER2+ breast cancers the percentage of HRD was higher in the metastatic lesions compared to another cohort of primary breast cancers. It is of the utmost importance to determine whether these observations are maintained when the HRD test is performed on more metastatic breast cancer patients. Therefore, we want to enlarge the group of BR grade 3 ER/PR+ metastatic breast cancers to prove that within the BR grade 3 ER/PR+ breast cancers the percentage of HRD is indeed significantly increased in the metastatic lesions compared to primary breast cancers. This could have great clinical implications, in terms of prognosis as well as therapeutically.
Doel van het onderzoek
This study will investigate whether within BR grade 3 ER/PR+ or HER2+ breast cancers the percentage of homologous recombination deficiency is substantially higher in metastatic lesions compared to primary breast cancers.
Onderzoeksopzet
na
Onderzoeksproduct en/of interventie
na
Publiek
A. Jager
Groene Hilledijk 301
Rotterdam 3075 EA
The Netherlands
Tel 010 704 17 33
a.jager@erasmusmc.nl
Wetenschappelijk
A. Jager
Groene Hilledijk 301
Rotterdam 3075 EA
The Netherlands
Tel 010 704 17 33
a.jager@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Breast cancer patients with local recurrent or distant metastases
- The site of the tumor should be easy amendable for biopsy. NB: lung metastases (high risk of hematothorax) and bone metastases (not suitable for ex vivo HRD test because calcifications interfere with experimental procedures) are excluded.
- Age >18 years
- WHO performance status 0 or 1
- Bilirubin <1.5 ULN and both AST and ALT <5x ULN in case a liver biopsy is planned
- Platelets >100 x 10e9/L and INR <1.5, unless platelet/INR values are not necessary according to local protocols or after consent of the intervention radiologist for that particular site of biopsy (e.g. biopsy of the skin).
- Written informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Current therapeutically use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH if used for prophylaxis is allowed. Use of low molecular weight heparin (LMWH) should be interrupted shortly before biopsy is scheduled, unless this is not necessary according to local protocols or after consent of the intervention radiologist.
- Any psychological condition potentially hampering compliance with the study protocol
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6376 |
| NTR-old | NTR6560 |
| Ander register | : MEC17-213 Erasmus Medisch Centrum |